Pestell Lab 

 

2017: Dr Pestell President of the Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center, was given the Jamie Brook Lieberman Honor for exceptional cancer care. Josh Lieberman, Carole Lieberman, Dr. Richard Pestell (accepting the Jamie Brooke Lieberman Honor) and Jules Lieberman. The Brook Lieberman Remembrance Award celebrates the life and legacy of a women taken by breast cancer at the young age of 35. The award is bestowed on an individual who, like Jamie, show a commitment to the cause, who want to lead in making a significant change, and who not only have hope in the cures but are every day in pursuit of saving lives.

Related links

Collaborative links

2015. Dr Pestell Received Global Australia award

The Pestell Laboratory is addressing fundamental questions in breast cancer and prostate cancer. The Pestell laboratory is located at Lankenau Institute for Medical Research. The Pestell laboratory deploys the shared resources of three institutions, the Wistar Institute, the Lankenau Institute for Medical Research and the Blumberg Institute of Living Sciences. The collective critical scientific mass of the three Institutes is substantial including LIMR as the home to 14 PI and 41 research personnel, the Wistar 20 PI and 276 researchers, and the Blumberg with 15 PI, 26 Faculty and 205 researchers. 


Dr. Pestell’s research in breast cancer, prostate cancer, oncology,cell cycle, and stem cells is highly cited with >53,000 citations (H index 123). He is ranked 8th in the world by Google scholar citations for breast cancer, first in the world  in cell cycle,  first in prostate cancer, and third in the world for oncology (ref)


In the area of breast cancer the Pestell Laboratory is defining the molecular mechanisms governing triple negative breast cancer progression and therapy resistance. With generous support from the Breast Cancer Research Foundation, the laboratory has defined a novel tumor suppressor (Dach1)  that governs breast cancer stem cell expansion. The laboratory is identifying novel mechanisms to augment Dach1 function, via a phosphatase Eya, and thereby restrain breast cancer stem cells and improve outcome for patients with triple negative breast cancer (Ref). 


In the area of prostate cancer the laboratory has been examining novel functions of cyclin D1 to restrain prostate cancer autophagy and to promote prostate cancer stem cell expansion (Ref). We have identified novel mechanisms governing cyclin D1 function independent of its kinase activity, which will enable alternative approaches to activate the non canonical functions of cyclin D1 (Ref). These mechanisms involve distinct Zip codes which send cyclin D1 to distinct subcelluar compartments to convey oncogenic activity. These functions include governing miRNA processing, chromatin remodeling, interaction with nuclear lamina and transcriptional induction of chromosomal instability, for breast cancer references please see (Ref). In order to facilitate rapid exchange of information with other breast and prostate cancer cancer research researchers the laboratory works closely with PCARM in the domain of cancer stem cell research




Our Mission

Dr Barry Marshall visited a Pestell's lab member, Dr. Yu Zuoren, at Shanghai East Hospital.